USMEDSA Urology Coordinating Team 2000 Accomplishments vs Objectives OBJECTIVES ACCOMPLISHMENTS Coordinate Merck Activities & Exhibits at Medical Meetings • Very successful exhibit presence at AUA 2000 Annual Meeting, Pri-Med, AACE & AAFP meetings • Sponsored BPH Week as part of AFUD’s 2nd Annual Prostate DUCATE PHYSICIANS
Health Month • AUA Annual meeting: hosted Merck Advocate Event (450 Uro’s), sponsored- AUA CME BPH Symposia (650 Uro’s), AUA Education Store, AUA CD ROM of Course Handouts (6000 MD’s), AUA Website, Abstracts Online, & Annual Meeting Planner • Provided the Audience Response System for the AUA Board Review Courses • Supported the: AUA Long Range Strategic Planning, AUA Chiefs of Urol Program, AUA/EAU Exchange Program ABOUT DATA FOR PROSCAR Provide Medical & Scientific Information • Conducted 3 Regional CME Programs, “Advances in the Eval. & Pharmacologic 3)3
Tx of BPH”. Monograph published & will be posted on Medscape for CME credit for 1 yr • Developed AND ASSIST IN THE LAUNCH OF
exhibits for AUA 2000 Annual Meeting (& sponsored CD ROM), Pri-Med Meetings, AACE & AAFP meetings. • Sponsored AUA CME program that is being evaluated by Audio Digest for inclusion in its tape program. • Worked with Annenberg Center for Health Sciences to create a Journal Plus Program (CME) on “The Role of Serum PSA in BPH” • Database updated with all product AUA abstracts, HCP’s product & disease questions answered in writing &/or by personal calls. • *Ongoing participation in MRL manuscript review/revision process, & Medical School Grant Committee • *Prostatitis & Hematuria MSGP’s- Assisted US investigators with investigator-IND application, provided investigators with double-blind THE PSA LABEL CHANGES
medication via outside vendor • * Participated in WPCRC activities related to the cir
cular additions on the relationships of PSA to prostate volume, PSA to outcomes, & prostate volume to outcomes. • * Collected & analyzed competitive product
information at AUA (alpha blockers, Dutasteride, herbal products)
Training of Urology Sales Force • High quality training lectures given to sales force trainees—top rating given by sales trainees • Trained sales force on key promotional piece “A Profile of Proscar” • Pro-actively wrote three SUPPORT MARKETING AND
Medical Background texts & tests for PSA launch • Reviewed/edited & assisted in writing sales bulletins (e.g., PREDICT study, Dr. Pitt’s negative editorial in J Urol) Medical Review & Assistance in Development of Promotional Materials • Participation in M/L boards • Researched & provided medical literature to support promotional efforts • Assistance to TBG & legal in drafting SALES TEAMS WITH
promotional materials by providing product, medical & urological expertise (e.g., “A Profile of Proscar”, “BPH: A Primary Care Perspective”, review of all key studies ‘92-’00) • * M/L board liaison with MRL MEDICAL & SCIENTIFIC Issue Research & Analysis Responded to 1
00% of Issues • Ongoing monitoring of the finasteride & competitive disease literature & the Internet, for US MEDSA, TBG, WHHM & MRL (e.g., quarterly alfusozin searches for
MEDSA & TBG; identification of AUA abstr
acts of interest for the Merck AUA meeting book) • *Ongoing extensive literature & database research & analysis (e.g., intraprostatic DHT levels; Lower Urinary Tract Symptoms) INFORMATION • *Participation in USHH-MRL-WHHM Prostate Cancer Product Development Team Work With Marketing to Develop & Execute a Plan to Train Sales Force • Developed MEDSA Dutasteride plan • *Created outline, provided source materials and reviewed WHHM MB (outline and source material being incorporated into promotional slide set) • Assisted TBG in planning & implementing promotional strategy to pre-empt Glaxo • *Created & gave training lectures to both HSA’s & to USHH team Issue Research and Analysis • Performed 100% of liter
ature searches & analyses • *Acti H
ve participants in the USHH team & USHH/WHHM/MRL Counterstrategy Task Force to plan & implement strategy • *Assisted TBG in analyzing
competitive data, planning & implementing counter- & promotional-strategy to pre-empt Glaxo
DUTASTERIDE Search and Monitor Product and Competitive Literature • Quarterly Literature Search on Dutasteride • Performed quarterly surveillance literature searches for the task force (TBG, MRL, WHHM) Search and Monitor Literatur PREPARE FOR THE M3 ANTAGONIST† e, Databases, and Internet • Begin to Develop Center of Expertise in Neurourology • Provided literature for new product marketing, market research, etc. • Collected voiding dysfunction
& incontinence related material at AUA •
Identified texts for library • Assisted in early strategic planning – PENDING PHASE IIB TRIAL RESULTS †Did not continue into Phase III Henry Rodrique, APA; Joanne Palmisano, Lee Halper, CDP; Leonard Silverstein (chair), Kathleen Peeples-Lamirande, Medical Services; Tom Abbott, ORM; Fran Kaiser, RMD
Designed and Produced by the DTP Group/InfoManagement Team/Medical Services
Dr Neil MacFarlane NICE and adult ADHD: an independent view This talk was given as a “workshop” session at The Ninth International ADDISS Conference, London, on 1st April 2009. The conference was attended by a range of people with ADHD, parents, and professionals. My views about the NICE guidance had previously been largely unexplored, but I previously had several discussions about
CIGNA Drug List Changes – Second Quarter 2009 CIGNA periodically reviews its drug list to promote continued effectiveness. Based on that review, the following changes have been made to the CIGNA drug list from April 1, 2009 to June 30, 2009. Drugs marked with an (*), (^), or (~) indicate that prior authorization, quantity limit, or step therapy is required, respectively. Note: This list